PTX.AX - Prescient Therapeutics Limited

ASX - ASX Delayed price. Currency in AUD
Show:
Income statement
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
30/06/2019
30/06/2018
30/06/2017
30/06/2016
Total revenue
-
-
-
-
10.704
Gross profit
-
-
-
-
10.704
Operating expenses
Research development
3,470
3,682
2,057
2,432
797.889
Selling general and administrative
2,049
1,863
1,549
1,331
1,952
Total operating expenses
5,519
5,545
3,606
3,763
2,750
Operating income or loss
-5,519
-5,545
-3,606
-3,763
-2,739
Interest expense
-
3.301
2.2
-
-
Total other income/expenses net
1,549
1,679
909.327
1,029
984.754
Income before tax
-3,900
-3,797
-2,574
-2,568
-1,754
Income tax expense
0
0
0
0
0
Income from continuing operations
-3,900
-3,797
-2,574
-2,568
-1,754
Net income
-3,900
-3,797
-2,574
-2,568
-1,754
Net income available to common shareholders
-3,900
-3,797
-2,574
-2,568
-1,754
Basic EPS
-
-0.02
-0.01
-0.01
-0.02
Diluted EPS
-
-0.02
-0.01
-0.01
-0.02
Basic average shares
-
244,545
214,012
212,582
83,204
Diluted average shares
-
244,545
214,012
212,582
83,204
EBITDA
-
-3,794
-2,572
-3,763
-2,739